整合全基因组关联研究与多组学数据探索增生性瘢痕的分子机制及治疗优化
本研究利用eQTLGen联盟、Decode数据库和FinnGen队列的汇总统计数据进行全转录组和全蛋白质组孟德尔随机化分析,发现成纤维细胞生长因子受体1(FGFR1)高水平显著增加增生性瘢痕风险(转录组P=0.011,蛋白质组P=0.002),RNA测序验证FGFR1在增生性瘢痕中高表达,药物预测与分子对接显示Ro-4396686与FGFR1稳定结合。
要点
- FGFR1高水平与增生性瘢痕风险增加显著相关
- 转录组和蛋白质组MR均支持FGFR1为致病核心基因
- Ro-4396686与FGFR1预测可稳定结合,具候选药物价值
核心结论
- FGFR1可作为优化增生性瘢痕治疗的潜在靶点,有望降低药物开发成本。
研究设计与样本
- 利用eQTLGen联盟、Decode数据库和FinnGen队列的汇总统计数据进行全转录组和全蛋白质组孟德尔随机化分析,并通过RNA测序验证。
主要发现
- 全转录组MR显示FGFR1高水平显著增加增生性瘢痕风险(P=0.011)。
- 全蛋白质组MR显示FGFR1高水平显著增加增生性瘢痕风险(P=0.002)。
- RNA测序验证FGFR1在增生性瘢痕中高表达。
- 基因-基因互作网络和富集分析确定FGFR1为驱动增生性瘢痕进展的核心基因,突出多个生物合成过程。
- 药物预测与分子对接显示Ro-4396686与FGFR1之间预测可稳定结合。
临床怎么用
- FGFR1可作为增生性瘢痕药物开发的候选靶点,Ro-4396686值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic scar (HS) represents a skin fibroproliferative disease characterized by a high incidence, frequent recurrence, and limited treatment options. Thus, identifying new targets to optimize the treatment of HS is of critical importance. METHODS: Using summary statistics from the eQTLGen Consortium, Decode database, and FinnGen cohort, we conducted transcriptome-wide and proteome-wide Mendelian randomization (MR) to discover potential pharmacological targets against HS, with subsequent validation via RNA sequencing. Upstream regulators and downstream mechanisms were further investigated to better understand the roles of the pathogenic gene. Drug prediction, molecular docking, and molecular dynamics (MD) simulation were employed to estimate the value of potential drugs for HS. RESULTS: A high level of fibroblast growth factor receptor 1 (FGFR1) significantly increased the risk of HS according to transcriptome-wide (P = 0.011) and proteome-wide MR (P = 0.002) analyses. RNA-seq further validated the high expression of FGFR1 in HS. Gene-gene interaction network and enrichment analysis identified FGFR1 as the core gene driving the progression of HS, highlighting multiple biosynthetic processes. Pharmacological evaluation of candidate drugs predicted stable binding between Ro-4396686 and FGFR1. CONCLUSIONS: Our findings suggest that FGFR1 can serve as promising target for optimizing HS treatments, potentially reducing the costs of drug development.
引用
- Zhang Z, Lian J, Zhang Z, et al. Exploring the molecular mechanisms and optimizing treatment of hypertrophic scar by integrating genome-wide association studies and multi-omics data. Burns. 2026. PMID: 41740536. doi:10.1016/j.burns.2026.107919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。